Latest News in the pharma Industry
Research & Development
Proclara Biosciences Australia awarded grant to help develop new biotherapy with blockbuster potential
12 Mar 2017
Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.
Read more
Bavarian Nordic announces collaboration to evaluate CV301 and Tecentriq in bladder cancer
12 Mar 2017
Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.
Read more
Horizon Discovery enters into R&D and licensing partnership for bioproduction cell line optimisation
9 Mar 2017
Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.
Read more
FDA accepts sNDA for Vraylar
8 Mar 2017
Application seeks to expand Vraylar label to include Phase III clinical data for the maintenance treatment of schizophrenia.
Read more
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
7 Mar 2017
Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.
Read more
Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis
6 Mar 2017
Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.
Read more
GSK study shows Nucala significantly improves quality of life and lung function in severe asthma patients
6 Mar 2017
Provides hope for patients with severe asthma, who currently have very limited treatment options.
Read more
Sandoz proposed biosimilar adalimumab demonstrates equivalent efficacy as Humira
6 Mar 2017
Comprehensive development program show potential of GP2017 to treat inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.
Read more
Sanofi Pasteur and MedImmune collaborate on monoclonal antibody to prevent illnesses associated with RSV
4 Mar 2017
MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.
Read more
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild-type mCRC
2 Mar 2017
More patients now able to receive a standard-of-care treatment with Erbitux plus Folfiri or Folfox.
Read more
Astellas and Affinivax announce worldwide partnership for MAPS vaccine targeting pneumococcal disease
2 Mar 2017
Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.
Read more
FDA accepts BLA for avelumab for the treatment of metastatic urothelial carcinoma for Priority Review
28 Feb 2017
Second Biologics License Application accepted by the FDA for avelumab.
Read more